The first human-derived cells optimised for COVID-19 vaccine/drug development and safety assessment


Current issues for scientists developing COVID vaccine and drugs


Monkey-derived cells (VeroE6/TMPRSS2) are used for cell-based assay for the SARS-CoV-2 virus infection, however, development of human-derived cells with convenient formats have been required for smoother clinical trial and more detailed cell functional assays.


Benefit to introduce cMylc for COVID vaccine development


MiCAN’s cMylc (coronavirus-optimised myeloid lineage cells) are designed with a concept of detecting ADE (antibody-dependent enhancement) as the cMylc contains antibody Fc receptors, which enables scientists to increase the safety in the vaccine development processes. cMylc may be the first human myeloid lineage cells optimised for COVID-vaccine development using stem cell technologies suitable for scale-up and high reproducibility. The cMylc is cryopreserved with kit format so that scientists can simply follow the thawing protocol to start the analysis without confusions.



MiCAN looking for global industrial collaborators


MiCAN is ready to provide the cMylc as a convenient production format, but also looking for technical partners from the global leading pharmaceutical companies and emerging biotechnology startups. Please contact us via email or partnering page before 31 March 2021.




Who is MiCAN??


MiCAN Technologies is headquartered in Kyoto having technologies and licenses to produce high function human myeloid lineage cells (Mylc) from human iPS cells. The development and the feasibility studies to launch the cMylc has been conducted with a collaboration to the Research Institute for Microbial Diseases at Osaka University. Biospire, early-stage global technology management consultant, is supporting MiCAN’s global business development and alliance management as well as advising global product logistics and procurement. See https://www.biospire-global.com/mican-technologies for further information.